These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 11770860

  • 1. Inflammatory mechanisms in atherosclerosis: from laboratory evidence to clinical application.
    Blake GJ, Ridker PM.
    Ital Heart J; 2001 Nov; 2(11):796-800. PubMed ID: 11770860
    [Abstract] [Full Text] [Related]

  • 2. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
    Li JJ, Fang CH.
    Med Hypotheses; 2004 Nov; 62(4):499-506. PubMed ID: 15050096
    [Abstract] [Full Text] [Related]

  • 3. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S, Ridker PM.
    Am J Cardiol; 2006 Jan 16; 97(2A):33A-41A. PubMed ID: 16442935
    [Abstract] [Full Text] [Related]

  • 4. Inflammation, C-reactive protein, and atherothrombosis.
    Ridker PM, Silvertown JD.
    J Periodontol; 2008 Aug 16; 79(8 Suppl):1544-51. PubMed ID: 18673009
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein.
    Koenig W.
    Int J Cardiol; 2005 Feb 15; 98(2):199-206. PubMed ID: 15686768
    [Abstract] [Full Text] [Related]

  • 7. Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary events.
    Ridker PM, Shih J, Cook TJ, Clearfield M, Downs JR, Pradhan AD, Weis SE, Gotto AM, Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) Investigators.
    Circulation; 2002 Apr 16; 105(15):1776-9. PubMed ID: 11956118
    [Abstract] [Full Text] [Related]

  • 8. Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence.
    Zambon A, Gervois P, Pauletto P, Fruchart JC, Staels B.
    Arterioscler Thromb Vasc Biol; 2006 May 16; 26(5):977-86. PubMed ID: 16424352
    [Abstract] [Full Text] [Related]

  • 9. High-sensitivity C-reactive protein is the most effective prognostic measurement of acute coronary events.
    Futterman LG, Lemberg L.
    Am J Crit Care; 2002 Sep 16; 11(5):482-6. PubMed ID: 12233975
    [Abstract] [Full Text] [Related]

  • 10. The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen.
    Wilson AM, Ryan MC, Boyle AJ.
    Int J Cardiol; 2006 Jan 26; 106(3):291-7. PubMed ID: 16337036
    [Abstract] [Full Text] [Related]

  • 11. C-reactive protein and atherosclerosis: quo vadis?
    Koenig W, Torzewski J.
    Ital Heart J; 2001 Nov 26; 2(11):801-3. PubMed ID: 11770861
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
    Pearson TA, Ballantyne CM, Veltri E, Shah A, Bird S, Lin J, Rosenberg E, Tershakovec AM.
    Am J Cardiol; 2009 Feb 01; 103(3):369-74. PubMed ID: 19166691
    [Abstract] [Full Text] [Related]

  • 15. [Correlation of high-sensitivity CRP concentration with the extent of coronary atherosclerosis in men with symptoms of ischemic heart disease].
    Piechota W, Piechota W.
    Pol Merkur Lekarski; 2005 May 01; 18(107):511-5. PubMed ID: 16161944
    [Abstract] [Full Text] [Related]

  • 16. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.
    Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, Szarek M, Libby P, Ganz P, Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators.
    Circulation; 2003 Sep 30; 108(13):1560-6. PubMed ID: 12975259
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. How to use the C-reactive protein in cardiac disease?
    Ursella S, Mazzone M, Portale G, Testa A, Pignataro G, Covino M, Fenici P, Gasbarrini GB, Gentiloni Silveri N.
    Minerva Cardioangiol; 2005 Feb 30; 53(1):59-68. PubMed ID: 15788980
    [Abstract] [Full Text] [Related]

  • 19. Changes of plasma inflammatory markers after withdrawal of statin therapy in patients with hyperlipidemia.
    Li JJ, Li YS, Chu JM, Zhang CY, Wang Y, Huang Y, Chen J, Yuan JQ, Huang YL.
    Clin Chim Acta; 2006 Apr 30; 366(1-2):269-73. PubMed ID: 16343471
    [Abstract] [Full Text] [Related]

  • 20. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment.
    Libby P, Ridker PM.
    Am J Med; 2004 Mar 22; 116 Suppl 6A():9S-16S. PubMed ID: 15050187
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.